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Introduction
Tregs are essential for maintenance of immune homeostasis and 
self-tolerance (1, 2). These cells also dampen host antitumor immu-
nity, decreasing the efficacy of tumor immune surveillance (3). The 
key transcription factor Foxp3 has a critical role in the differentiation 
and function of Tregs (4, 5), and knockdown or mutations of Foxp3 
attenuate the immunosuppressive capacity of Tregs (6, 7). Similarly, 
depletion of Foxp3+CD4+ Tregs results in severe autoimmunity in 
otherwise normal animals and can be reversed by reconstituting 
Tregs (8, 9). Recent successes with checkpoint inhibitor therapies in 
the treatment of various cancers have rekindled interest in immu-
notherapy. However, despite a major contribution of Foxp3+ Tregs 
to establishing and maintaining an immunosuppressive tumor 
microenvironment, there are very few options to selectively target 
Foxp3+ Tregs and promote antitumor immunity (10).
REST corepressor 1 (Rcor1 or CoREST) is a protein that 
binds to the C-terminal domain of REST and regulates diverse 
immune and inflammatory responses (11). Rcor1 is best known as 
a core component of the chromatin-modifying CoREST repres-
sor complex (12), which also includes histone deacetylase 1 or 2 
(Hdac1/2) (13–15) and the histone 3 lysine 4 (H3K4) demethylase 
Lsd1 (Kdm1a) (16, 17). HDAC1/2 removes acetyl groups from his-
tone tails, and Lsd1 removes monomethylation and/or dimeth-
ylation marks from H3K4 (18). Much attention has been focused 
on understanding the biochemical functions of Rcor1 in various 
tissues. In patients with diffuse large B cell lymphoma, deletions 
in Rcor1 are associated with unfavorable progression-free survival 
(19). Rcor1 also recruits the INSM1/Rcor1/2 complex, controlling 
the balance of proliferation and differentiation during brain devel-
opment (20). In hematopoietic stem cells, loss of Rcor1 in adults 
leads to a complete block in erythroid and neutrophil differenti-
ation (21). Although Rcor1 functions as an epigenetic and repres-
sive factor in immune cells, its role in the regulation of Foxp3+ 
Tregs has not been studied. Accordingly, we conditionally deleted 
Rcor1 in Tregs and tested the effects of recently characterized 
dual Hdac1/2 and Lsd1 (CoREST) inhibitors. We found that gene 
deletion or pharmacologic inhibition disrupted Foxp3-dependent 
recruitment of the CoREST complex to the promoters of T-bet, 
IL-2, and IFN-γ, leading to Treg production of IL-2 and IFN-γ, 
impaired Treg function, and enhanced antitumor immunity.
Results
Foxp3, Rcor1, and the CoREST complex. Foxp3 has a central role in 
maintaining Treg stability and function and forms multiprotein 
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To further characterize the Rcor1–/– mice, sec-
ondary lymphoid tissues were harvested, single-cell 
suspensions prepared, and cell populations and acti-
vation markers assessed by flow cytometry. Rcor1–/– 
mice showed moderately decreased proportions of 
Foxp3+CD4+ Tregs within lymph nodes and spleen (Fig-
ure 2A), and there were only a few significant differ-
ences in basal T cell activation markers in lymph nodes, 
spleen, or thymus, including increased proportions 
of splenic CD69+CD8+ T cells, decreased proportions 
of splenic CD4+CD69+ T cells, and increased levels of 
CD44hiCD62Llo CD8+ T cells in lymph nodes (Figure 2B). 
The in vitro suppressive functions of Tregs from Rcor1–/– 
mice were significantly (though modestly) impaired (P 
< 0.05) compared with those of WT Tregs (Figure 2C, quanti-
fied in Supplemental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/JCI131375DS1). 
Hence, Foxp3 can associate with Rcor1 and Lsd1 components of 
the CoREST complex, and under basal conditions, Rcor1 dele-
tion leads to decreases in peripheral Treg numbers and Treg 
suppressive function in vitro.
We wondered whether the lack of a phenotype under steady-
state conditions in the Rcor1–/– mice might reflect compensation 
by Rcor2 and briefly explored this by developing mice with con-
ditional deletion of Rcor2 (Rcor2fl/flFoxp3YFP/Cre) or both Rcor1 and 
Rcor2 (Rcor1fl/flRcor2fl/flFoxp3YFP/Cre) in their Tregs. Conditional 
deletion of Rcor2 led to a small decrease in peripheral Treg pro-
portions in peripheral lymphoid tissues similar to that seen with 
Rcor1 deletion (Supplemental Figure 2A). However, in contrast 
to what occurred with Rcor1, deletion of Rcor2 led to a modest 
increase (P < 0.05) in Treg suppressive function (Supplemental 
Figure 2B). Dual deletion of Rcor1 and Rcor2 decreased thy-
mic Treg production, and their peripheral Tregs had somewhat 
impaired Treg function (P < 0.05) similar to that seen with Rcor1 
deletion (Supplemental Figure 2, A and B). Under steady-state 
conditions, deletions of Rcor1, Rcor2, or both Rcor1 and Rcor2 
in Tregs did not lead to marked changes in activation of CD4+ 
or CD8+ T cells (Supplemental Figure 2C). These data, while not 
exhaustive, suggest that Rcor1 plays a dominant role in Tregs that 
is not able to be duplicated by Rcor2.
complexes (≥400–800 kDa) that include various transcription 
factors and repressor complexes (22), though the functions of 
these evolutionarily highly conserved repressor complexes are 
largely unexplored. We analyzed the roles in Tregs of the CoREST 
scaffolding proteins Rcor1 and Rcor2 and their associated 
enzymes Hdac1, Hdac2, and Lsd1. In 293T cells transfected with 
tagged constructs, IP of Foxp3 led to co-IP of Rcor1 (44 kDa), but 
not Rcor2 (53 kDa, Figure 1A). In reciprocal studies, IP of Rcor1 led 
to co-IP of Foxp3 as well as Rcor2 and p300 (Figure 1B). We have 
previously shown that IP of Foxp3 leads to co-IP of p300, which is 
important for Foxp3 acetylation, dimerization, and Treg function 
(23). The association of Rcor1 with Foxp3 was also demonstrated 
using Tregs; IP of Rcor1 led to co-IP of Foxp3 (Figure 1C), and IP 
of Foxp3 led to co-IP of Rcor1 (Figure 1D). Hence, Rcor1 can asso-
ciate with Foxp3 and with Rcor2 as part of the CoREST complex.
We next conditionally deleted Rcor1 in Foxp3+ Tregs by cross-
ing Rcor1fl/fl and Foxp3YFP/Cre mice (Figure 1E). Rcor1fl/flFoxp3YFP/Cre 
(hereafter Rcor1–/–) mice were born at expected Mendelian ratios 
and, upon monitoring for up to 1 year, developed normally, with-
out development of weight loss, dermatitis, lymphadenopathy, 
splenomegaly, histologic abnormalities, or other evidence of auto-
immunity. To determine whether Treg deletion of Rcor1 affected 
Foxp3 association with the CoREST complex, we undertook IP 
of Lsd1 and Western blotting of immunoprecipitates for Foxp3. 
Unlike in WT Tregs, the association of Foxp3 with the Lsd1 was 
largely lost in Rcor1–/– Tregs (Figure 1F).
Figure 1. Association of Foxp3 with the CoREST complex. (A) 
In HEK-293T cells transfected with tagged constructs encoding 
Foxp3 (47 kD), Rcor1 (44 kD), and Rcor2 (53 kD), IP of Foxp3 led 
to co-IP of Rcor1 but not Rcor2 protein. (B) In HEK-293T cells 
transfected with the same Foxp3, Rcor1, and Rcor2 constructs 
as shown in A, plus HA-tagged p300, IP of Rcor1 led to co-IP of 
Foxp3, Rcor2, and p300. (C) Lysates of Tregs isolated from lymph 
nodes and spleens of WT B6 mice were subjected to IP using 
anti-Rcor1 Ab or control IgG; Rcor1 and Rcor1-associated Foxp3 
were detected by immunoblotting. (D) Tregs isolated from B6 
lymph nodes and spleens after expansion in vivo (rIL-2/anti–IL-2, 
3 days) were subjected to IP using anti-Foxp3 Ab or control IgG; 
shown is IB detection of Foxp3 and Foxp3-associated Rcor1. (E) 
Western blots of Rcor1 and Foxp3 expression in Tregs and Teff 
cells from WT mice or those with conditional deletion of Rcor1 in 
their Tregs; β-actin was used as a loading control. (F) IP of Lsd1 
from WT Tregs led to co-IP of Foxp3, whereas IP of Lsd1 from 
Rcor1–/– Tregs led to only trace levels of Foxp3 co-IP.
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showed enrichment of genes associated with inflammatory and 
immune responses in Rcor1–/– versus WT Tregs (Figure 3F).
Treg expression of cytokines such as IL-2 and IFN-γ is nor-
mally highly suppressed, and epigenetic mechanisms are thought 
to contribute to such regulation. Hence, we used ChIP analysis 
to assess chromatin remodeling at relevant gene promoters as a 
result of Rcor1 deletion. We pulled down chromatin with antibod-
ies directed against Lsd1, Hdac1, Hdac2, or acetylated histone 3 
(ac-histone 3) and analyzed by qPCR the levels of the promot-
ers of IL-2, IFN-γ, and T-bet that were co-immunoprecipitated. 
Compared with WT Tregs, Rcor1–/– Tregs had dramatic decreases 
of Hdac2 and LSD1, no significant difference in HDAC1, and a 
marked increase of ac–histone 3 at the IL-2 promoter (Figure 4A). 
Likewise, Rcor1–/– Tregs showed decreased Lsd1/Hdac1/Hdac2 
and increased ac–histone 3 binding at the IFN-γ promoter (Fig-
ure 4B). IFN-γ is a signature cytokine of CD4+ Th1 cells, and its 
expression is regulated by T-bet (T-box1). Rcor1–/– Tregs showed 
decreased Hdac1/Hdac2 and increased ac–histone 3 at the T-bet 
promoter, but there was no significant difference in Lsd1 (Figure 
4C). Recent studies have highlighted the crossregulation of IFN-γ 
and STAT1 with β-catenin, including in dysfunctional Foxp3+ Tregs 
(24, 25). Although Rcor1–/– Tregs did not affect expression of T-bet 
and β-catenin proteins under basal conditions, their protein levels 
were significantly increased in Rcor1–/– Tregs upon activation by 
CD3/CD28 mAb–coated beads for 24 hours (Figure 4D). These 
data point to a key role of the CoREST complex in suppressing 
Treg production of cytokines that are characteristic of activated 
conventional T cells and only dysfunctional Tregs.
Rcor1 deletion disrupts the Hdac/Lsd1/CoREST complex in 
Tregs. The CoREST complex, whose primary components are 
Hdac1 or its paralog Hdac2, Lsd1, and the scaffolding protein 
CoREST/Rcor1, regulates chromatin remodeling and gene 
expression (14, 26, 27). Upon studying Rcor1 protein expression 
in Tregs, we found that Rcor1 was located in cytoplasm under 
basal conditions in WT Tregs, but after activation with CD3/
CD28 mAbs for 24 hours, Rcor1 translocated to the nucleus (Fig-
ure 5A), consistent with reports that phosphorylation of Rcor1 in 
T cells and other cells can lead to nuclear translocation of cyto-
plasmic Rcor1 (28, 29). Next, we found that the levels of Hdac2 
and Lsd1 proteins, but not those of Hdac1, were significantly 
decreased in Rcor1–/– Tregs (Figure 5B). The best studied modifi-
cation of core histones is the reversible acetylation of conserved 
lysine residues within N-terminal tails, as regulated by histone 
acetyltransferases (Hats) and Hdacs. A well-established feature 
Profound effects of Rcor1 deletion on gene expression in Tregs and 
derepression of IL-2 and IFN-γ. We undertook RNA-Seq analyses of 
Rcor1–/– and WT Tregs to assess Rcor1-dependent global changes 
in gene expression. There were 1074 genes downregulated and 
816 genes upregulated in Rcor1 KO Tregs (>2-fold, P < 0.05) com-
pared with WT Tregs (Figure 3A). A hierarchical clustering map 
for differential gene expression is shown in Supplemental Figure 
3. Differentially expressed genes included cytokines and chemo-
kines (Figure 3B), leukocyte antigens (Figure 3C), and transcrip-
tion factors (Figure 3D). Upregulation of various genes of inter-
est, including IL-2, IL-4, IL-10, IFN-γ, Stat1, Stat4, T-box1, CD73, 
CTLA4, Ebi3, ICOS, and CD25, was confirmed by quantitative 
PCR (qPCR) (Figure 3E and Supplemental Figure 4) as well as by 
flow cytometric analysis of cytokine production by activated Tregs 
(Supplemental Figure 5). Functional annotation clustering also 
Figure 2. Cellular effects of Rcor1 deletion in Foxp3+ Tregs. (A) Percent-
ages of CD4+Foxp3+ Tregs in lymph nodes, spleens, and thymi of WT and 
Rcor1–/– mice, shown as representative plots (left) and with statistical 
analyses (right). (B) T cell activation markers in CD4+ and CD8+ T cells of 
WT and Rcor1−/− mice were analyzed as percentages of gated cells; data 
shown are representative of 4 to 6 experiments (left). Statistical analyses 
are shown (right). In (A) and (B) data are shown as mean ± SD, 6 to 8 mice/
group. Student’s t test for unpaired data. *P < 0.05 vs. WT control. (C) Treg 
suppression assays were performed using pooled (4 mice/group) Tregs 
and Teff cells from lymph nodes and spleens of WT and Rcor1–/– mice, as 
indicated. Assays were run in triplicate and repeated at least 3 times. The 
results of a representative experiment are shown, along with the percent-
ages of proliferating cells in each panel.
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indicate that Rcor1 is important to maintaining CoREST com-
plex–dependent functions in Tregs.
Rcor1 deletion disrupts Treg function in vivo and promotes anti-
tumor immunity. We used 3 animal models to assess the effects 
of Rcor1 deletion on Treg function in vivo (23, 30). First, we 
tested the ability of Tregs to inhibit homeostatic proliferation of 
conventional T cells over 7 days following their adoptive transfer 
into immunodeficient mice. Cotransfer of WT Tregs significantly 
inhibited T effector (Teff) cell proliferation, whereas Rcor1–/– 
Tregs were less able to suppress Teff cell proliferation (P < 0.05, 
Figure 6A) and showed upregulation of IFN-γ production (Supple-
mental Figure 6A). Analogous adoptive transfer with follow-up 
at 30 days again showed markedly greater expansion of Teff 
cells in the presence of Rcor1–/– vs. WT Tregs and suggested that 
decreased viability of yellow fluorescent protein–positive (YFP+) 
Rcor1–/– vs. WT Tregs may contribute to this difference, given 
the reduced number of viable Rcor1–/– versus WT Tregs (Figure 
6B). Rcor1–/– Tregs also showed increased production of IL-2 and 
IFN-γ compared with WT Tregs (Supplemental Figure 6B).
In a second in vivo test of Rcor1 deletion in Tregs, we under-
took cardiac allografts and treated recipients with CD40L (CD154) 
mAbs plus donor splenocyte transfusion (DST) (5 × 106). This 
well-established costimulation blockade protocol (31) induced 
long-term allograft survival in WT but not in Rcor1–/– recipients 
(Figure 6C), indicating the inability of Foxp3+ Tregs to control host 
alloresponses in the absence of Rcor1.
Third, we assessed whether Rcor1 deletion in Tregs promoted 
antitumor immunity, using TC1 and AE.17 lung tumor models. We 
have previously shown that the growth of these tumors in synge-
neic C57BL/6 mice is Treg dependent (23, 32). Compared with 
WT mice, Rcor1–/– mice displayed a profound reduction in AE.17 
tumor growth (Figure 6D). Flow cytometry analysis showed that 
Rcor1–/– mice had an increased frequency of tumor-infiltrating 
IFN-γ–producing CD8+ T cells (Figure 6E), and qPCR analysis 
showed increased CD4, CD8, IFN-γ, and granzyme-B mRNAs 
and decreased Foxp3 mRNA in tumors harvested from Rcor1–/– 
versus WT mice (Figure 6F). Related studies in the TC1 lung tumor 
model showed that, compared with WT controls, Rcor1–/– mice 
had decreased tumor growth (Figure 6G), increased tumor infiltra-
tion by IFN-γ+CD8+ T cells (Figure 6H), and increased CD4, CD8, 
IFN-γ, and granzyme-B mRNAs (Figure 6I). Finally, consistent with 
Treg dysfunction upon Rcor1 deletion, Rcor1–/– Tregs produced 
more cytokines (IL-2, IL-4, IFN-γ) than WT Tregs in tumor-associ-
ated lymph nodes and within the tumors themselves (Supplemen-
of CoREST is its ability to regulate H3K9 acetylation and H3K4 
demethylation (15–17). In Rcor1–/– Tregs, we found that H3K9 
acetylation (H3K9Ac) and H3K4 dimethylation (H3K4Me2) 
were increased compared with WT Tregs, consistent with 
reduced actions of the CoREST Hdac and Lsd1 enzymes (Figure 
5C). Likewise, overexpression of Rcor1 in 293T cells decreased 
the levels of H3K9Ac and H3K4Me2 (Figure 5D). These data 
Figure 3. RNA-Seq of Rcor1–/– vs. WT Tregs. (A) Volcano plot showing  
statistical significance (Padj) vs. fold change for genes differentially 
expressed as a result of Rcor1 deletion in Foxp3+ Tregs. (B–D) Heatmaps of 
fragments per kilobase of transcript per million mapped reads of (B) cyto-
kines and cytokine receptors, (C) leukocyte antigens, and (D) transcription 
factors in WT vs. Rcor1–/– Tregs. Data underwent Z score normalization for 
display. (E) qPCR results of gene expression in WT vs. Rcor–/– (R) Tregs that 
were freshly isolated or cultured under activating conditions for 24 hours 
(1:1 ratio of CD3/CD28 mAb-coated beads); data are shown as mean ± SD, 3 
mice/group. Student’s t test for unpaired data. *P < 0.05; **P < 0.01; ***P 
< 0.001 for the indicated comparisons. (F) Functional annotation clustering 
showed enrichment of genes associated with inflammatory and immune 
responses in Rcor1–/– versus WT Tregs.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 8 3 4 jci.org   Volume 130   Number 4   April 2020
into Rag1–/– cardiac allograft recipients led to 
long-term (>100 days) survival in the case 
of DMSO-treated mice, but resulted in acute 
allograft rejection in mice treated with JK-2-68 
(10 mg/kg/d, 14 days) (P < 0.01) (Figure 7B) or 
corin (P < 0.01, Supplemental Figure 9D). Like-
wise, the CD40L mAb–based costimulation 
blockade protocol resulted in long-term (>100 
days) allograft survival in DMSO-treated mice, 
but led to allograft rejection in recipients treated 
with JK-2-68 (P < 0.01) (Figure 7C). We also tested 
the effects of JK-2-68 on histone acetylation 
and demethylation in Foxp3+ Tregs and found 
that the levels of H3K9Ac and H3K4Me2 were 
markedly increased (Figure 7D). These results 
indicate that CoREST complex inhibition 
impairs the functions of murine Tregs in vitro and in vivo.
CoREST complex inhibitor impaired human Treg function. In par-
allel studies, preincubation of human Tregs with corin impaired 
Treg suppression of the proliferation of human CD4+ (Figure 8A) 
and CD8+ (Supplemental Figure 12) T cells. By staining cells har-
vested at the end of these suppression assays for the fixable live/
dead marker Zombie and Foxp3 and gating on CD4+CFSE– cells to 
define “dead Treg” Zombie+, “live exTreg” Zombie–Foxp3–, and 
“live Treg” Zombie–Foxp3+ cells, we found that corin exposure had 
decreased the numbers of live Tregs and increased the numbers 
of exTregs in these assays (Figure 8B). Statistical analyzes of these 
effects are shown in Figure 8, C and D, respectively. We also noted 
that corin had decreased Treg expression of Foxp3 and CTLA4 
(Figure 8E) and increased expression of CD127 (Figure 8F). Stud-
ies of the direct effects of corin on human PBMCs showed that the 
compound led to decreased proportions of Foxp3+ cells (Figure 8G) 
and decreased Foxp3 protein expression per Treg (Figure 8H, with 
statistical analyses in Figure 8, I and J, respectively). Hence, 
CoREST inhibitor treatment impaired human Treg suppressive 
function and was associated with decreased expression of Foxp3, 
CTLA4, and other genes associated with human Treg function.
CoREST complex inhibitor promotes antitumor immunity. 
Although the murine transplant data suggested that CoREST inhi-
bition preferentially affected the functions of Tregs versus Teff 
cells, since the net effect of systemic compound administration 
was to induce allograft rejection by host T cells, a far more use-
ful action would be to promote antitumor immunity, consistent 
with the effects we observed following Rcor1 deletion in Foxp3+ 
Tregs (Figure 6). For these studies, we turned to the use of corin, 
tal Figure 7). Thus, Rcor1 deletion in Tregs impairs Treg function 
and promotes antitumor immunity.
CoREST complex inhibitor impaired murine Treg function. Bifunc-
tional small molecules that jointly inhibit the Hdac and Lsd1 enzy-
matic activities of the CoREST complex were recently described 
(33). The structure of JK-2-68 is derived from phenelzine, while that 
of JKD-1-51 (also known as corin) is derived from tranylcypromine, 
and both compounds contain the same zinc-binding group that is 
derived from the HDAC inhibitor MS-275 (Supplemental Figure 
8). From a translational perspective, we questioned whether such 
bifunctional CoREST inhibitors would generate data in WT mice 
similar to that found upon disruption of the complex in Foxp3+ Tregs 
by Rcor1 deletion. Encouragingly, CoREST inhibitors impaired 
murine Treg suppressive function (Supplemental Figure 9), but did 
not affect the suppressive function of Rcor1–/– Tregs (Supplemen-
tal Figure 10). We next studied gene expression by purified WT 
Teff cells and Foxp3+ Tregs that were freshly isolated or stimulated 
overnight with CD3/CD28 mAb–coated beads in the presence of 
DMSO or CoREST inhibitor. CoREST inhibitor treatment resulted 
in increased gene expression of IL-17 and IFN-γ and decreased gene 
expression of Foxp3, CTLA4, GITR, and TGF-β by Tregs as well as 
increased IL-2, IL-10, and IFN-γ and decreased GITR and TGF-β 
expression by conventional T cells (Figure 7A). Treg induction of 
proinflammatory cytokines, upon CoREST inhibitor treatment, was 
also seen by flow cytometry (Supplemental Figure 11).
We next used 2 transplant models (34) that are both depen-
dent upon Foxp3+ Treg function for long-term allograft survival 
(>100 days) to screen for effects of CoREST inhibitors on immune 
responses in vivo. Adoptive transfer of Teff cells and Tregs (2:1 ratio) 
Figure 4. Rcor1 deletion promotes Treg expression 
of IL-2, IFN-γ, and T-bet. ChIP assays of (A) IL2, (B) 
Ifng, and (C) T-box1 promoters with pull-down Ab 
of Lsd1, Hdac1, Hdac2, and ac–histone 3 (ac-H3). (D) 
Representative bands and statistical analyses of 
Western blots for T-bet and β-catenin expression in 
fresh and 24 hour–stimulated (1:1 ratio of CD3/CD28 
mAb-coated beads) WT or Rcor1–/– Tregs and Teff 
cells harvested from corresponding mice. Data are 
shown as mean ± SD, 4–6 samples/group. Student’s 
t test for unpaired data. *P < 0.05; **P < 0.01; ***P 
< 0.001; ****P < 0.0001 vs. WT control.
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a more powerful and pharmacokinetically robust CoREST com-
plex inhibitor than JK-2-68 (33). Importantly, like JK-2-68, corin 
impaired Treg function in vitro and in vivo (Supplemental Figure 
9). Compared with DMSO-treated controls, syngeneic C57BL/6 
mice treated with corin had significantly reduced growth of TC1 
tumors (Figure 9A). This beneficial effect was accompanied by 
increased tumor infiltration by CD8+ T cells (Figure 9B), including 
CD8+IFN-γ+ T cells (Figure 9C). Tumor infiltration by Foxp3+ Tregs 
was unchanged by corin therapy (Figure 9D), but these cells now 
produced proinflammatory cytokines, including IL-2 and IFN-γ 
(Supplemental Figure 13). CoREST complex inhibitor therapy also 
promoted CD4+ and CD8+ T cell activation in secondary lymphoid 
tissues and increased tumor infiltration by 
effector/memory CD8+ T cells (Figure 9E). No 
direct effects on tumor growth were seen when 
tumor-bearing immunodeficient Rag1–/– mice 
were treated with CoREST complex inhibitor 
(Supplemental Figure 14). Hence, the inhibitor 
impaired tumor growth in WT mice by promot-
ing antitumor immunity. 
Discussion
Comparative studies of the 3 CoREST genes, 
encoding Rcor1 and its paralogs Rcor2 and 
Rcor3, indicate that all 3 CoREST proteins 
interact equally with Lsd1, but vary in their 
dependency on Hdac1/2 for their transcrip-
tional repression (35). CoREST complexes 
containing Rcor1 have the greatest transcrip-
tional repressive capacity (35). In the current 
studies, pulldown of Foxp3 led to co-IP of 
Rcor1 but not Rcor2, and pulldown of Lsd1 led 
to co-IP of Foxp3 only in the presence of Rcor1 
(Figure 1). These biochemical data suggest that 
Rcor1 and Lsd1 are important to Treg biology, 
consistent with the presence of Foxp3, Rcor1, 
Hdac1 or Hdac2, and Lsd1, but not Rcor2 or 
Rcor3, in large multiprotein complexes of 400 
to 800 kDa or more in Tregs (22). Also consis-
tent with a major role in Tregs of Rcor1 versus 
its paralogs, Rcor2 deletion had minimal effects on Tregs, and 
dual Rcor/Rcor2-deficient Tregs were similar to Rcor1–/– Tregs 
(Supplemental Figure 2). Under basal conditions, deletion of 
Rcor1 had only modest effects on Treg development and numbers 
in secondary lymphoid tissues, and Rcor1–/– mice developed nor-
mally and had no signs of autoimmunity when housed under spe-
cific pathogen–free conditions for up to a year. Upon activation in 
vitro, Rcor1 deletion or use of CoREST inhibitors promoted Treg 
production of proinflammatory cytokines but in the resting state, 
tissues were not infiltrated by host cells (Supplemental Figure 15). 
In contrast, our data from homeostatic proliferation studies, car-
diac transplant experiments, and tumor models all point to a crit-
Figure 5. Rcor1 deletion affects the functions of the 
CoREST complex in Tregs. (A) Localization of Rcor1 
and Foxp3 in Tregs. Representative of 3 independent 
experiments. Original magnification, ×400. Scale 
bars: 10 μm. (B) Representative bands (left) and 
statistical analysis (right) of Western blotting for 
HDAC1/2/LSD1 in Rcor1–/– versus WT Tregs (β-actin 
loading control). (C) Western blot of H3K4Me2 and 
H3K9Ac level in Rcor1–/– versus WT Tregs (total 
histone 3 as loading control) (left), and statistical 
analysis of Western blotting (right). (D) Western blot 
results of H3K4Me2 and H3K9Ac levels in 293T cell 
line after overexpression of Rcor1 compared with EV 
(β-actin loading control) (left) and statistical analysis 
of Western blotting (right). Data are shown as 
mean ± SD, 4–6 samples/group. Student’s t test for 
unpaired data. *P < 0.05; **P < 0.01; ***P < 0.001 
vs. WT control.
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ical loss of Treg function when Rcor1–/– mice were challenged by 
strong T cell activation in vivo. The apparent disconnect between 
minor effects in vitro and in vivo in Rcor1–/– mice under basal 
conditions compared with when subject to activating stimuli is 
not unusual, e.g., the ablation of Blimp1, Icos, IL-10, Ctla4, or 
Eos in Tregs does not affect their suppressive properties in vitro, 
but impairs their activation under stimulating conditions and 
their activities in vivo (36–41), similarly to what occurred in our 
Rcor1–/– mice. These data and our related findings using bifunc-
tional CoREST inhibitors in WT mice underscore the poten-
tial benefit of targeting this complex for therapeutic purposes, 
such as in cancer immunotherapy.
Figure 6. Rcor1 deletion impairs Treg function in vivo. (A) The ability of Rcor1 –/– Tregs (0.5 × 106) to dampen homeostatic proliferation at 7 days after adop-
tive transfer of Teff cells (1 × 106) into Rag1–/– mice was significantly decreased compared with the effects of corresponding numbers of WT Tregs (P < 0.05). 
(B) The stability of YFP+ Rcor1–/– Tregs (1 × 106) at 4 weeks after adoptive transfer of Teff cells (0.25 × 106) in Rag1–/– mice was significantly decreased com-
pared with the effects of corresponding WT Tregs, as shown by flow cytometric evaluation of viable cells. *P < 0.05; ***P < 0.001. (C) WT or Rcor1–/– mice (5 
mice/group) received BALB/c cardiac allografts plus CD40L mAb/DST; long-term allograft survival was seen in WT but not Rcor1–/– recipients (P < 0.01). (D–I) 
Treg-specific deletion of Rcor1 enhanced antitumor immunity. Tumor volumes and AUC data of AE17 (D) and TC1 (G) lung tumors were smaller in syngeneic 
Rcor1–/– vs. WT mice (n = 8–10/group) after inoculation and reached statistical significance (P < 0.05). Analysis of CD4+Foxp3+, CD4+, CD8+, and CD8+IFN-γ+ 
cells in lymphoid tissues from Rcor1–/– or WT mice, bearing AE17 (E) or TC1 (H) tumors. qPCR analysis of gene expression of CD4, CD8, IFN-γ, granzyme B, and 
Foxp3 in tumor samples of AE17 (F) or TC1 (I) harvested at the end of each experiment. Data are shown as mean ± SD, 4–6 samples/group. Student’s t test 
for unpaired data. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001 vs. WT control.
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tors, their DNA binding, and recruitment of transcriptional com-
plexes, as shown schematically in Figure 10.
The in vivo effects of Rcor1 deletion in Tregs were more potent 
than anticipated by our in vitro data, but are consistent with a 
reduced transcriptional repressive capacity compared with WT 
Tregs and decreased suppression of potent Teff responses induced 
by exposure to allogeneic cells and tumor antigens. We have shown 
that the ability of AE.17 and TC1 tumor cells to grow in syngeneic 
C57BL/6 mice is dependent upon the ability of Foxp3+ Tregs to 
suppress host Teff responses, especially that of CD8+ T cells pro-
ducing effector molecules such as IFN-γ and granzyme-B (23, 32). 
The findings that deletion of Rcor1 within Tregs of tumor-bearing 
mice had profound effects on tumor growth and immune-depen-
dent clearance points to a major role of the CoREST complex in 
control of Treg functions during potent immune responses. These 
events were not accompanied by an inability of Foxp3+ Tregs to 
accumulate at tumors, since flow cytometric studies showed that 
Treg numbers were unimpaired or even somewhat increased (Fig-
ure 6), possibly reflecting increased CXCR3 expression following 
Rcor1 deletion. Overall, the findings in Rcor1–/– mice are more 
consistent with disruption of function as a result of derepression 
Deletion of Rcor1 in Tregs increased the expression of mul-
tiple transcription factors, cytokines, chemokines, and their 
receptors, especially upon cell activation (Figure 3). Prominent 
among these effects were the induction of IL-2 and IFN-γ pro-
duction by Rcor1–/– Tregs, consistent with decreased recruitment 
of Lsd1, Hdac1 and/or Hdac2 to the Il2, Ifng, and T-box1 gene pro-
moters and increased histone-3 acetylation at these sites (Figure 
4). A key role of the CoREST complex in normally suppressing 
these events was further supported by the findings of increased 
H3K4Me2 and H3K9Ac in Rcor1–/– versus WT Tregs, consistent 
with decreased actions of Lsd1 and Hdac1/2, respectively, as 
well as by reversal of these features upon overexpression of Rcor1 
(Figure 5). Tregs are sensitive to changes in the amount of IL-2 
produced by CD4+Foxp3–CD44hi T cells, and this is thought to be 
a mechanism by which Treg abundance can be rapidly altered as 
the number of Teff cells fluctuates (42). Likewise, Foxp3 binds 
and prevents the expression of effector cytokine genes in Tregs 
(43). The disruption of the epigenetic regulation of IL-2, IFN-γ, 
and other genes in Tregs as a result of Rcor1 deletion points to 
additional levels of control and potential for therapeutic inter-
vention beyond regulation of the activation of transcription fac-
Figure 7. CoREST complex inhibitor 
affects Treg gene expression and 
function in vitro and in vivo. (A) 
qPCR analyses of indicated gene 
expression in Teff cells and Tregs. 
qPCR data were normalized to 
18S, and data (mean ± SD) are 
representative of 2 independent 
experiments involving 5 mice/group. 
*P < 0.05; **P < 0.01; ***P < 0.001; 
****P < 0.0001 vs. WT control. (B) 
Immediately after cardiac allograft-
ing from BALB/c donors, recipient 
C57BL/6 Rag1–/– mice (5 mice/
group) were adoptively transferred 
with 1 million B6 Teff cells and 0.5 
million B6 Tregs and treated with 
or without JK-2-68 (10 mg/kg/d, 14 
days). P < 0.01 for 2 groups. (C) B6 
recipients were transplanted with 
BALB/c cardiac allografts (5 mice/
group) and treated with CD40L 
mAbs (200 μg)/DST and JK-2-68 (10 
mg/kg/d, 14 days). P < 0.01 for 2 
groups. (D) Representative bands 
(left) and statistical analysis (right) 
of Western blotting for H3K4Me2 
and HK9Ac expression in fresh Tregs 
or Tregs stimulated for 24 hours by 
CD3/CD28 mAb-coated beads with 
or without JK-2-68 (10 μM).
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vivo use of these compounds could have effects beyond just Tregs, 
we first focused on testing effects of one such CoREST complex 
inhibitor, JK-2-68, on resting or activated Tregs and conventional 
T cells. In Foxp3+ Tregs, the inhibitor decreased expression of sev-
eral signature genes, including genes encoding CTLA4, Foxp3, 
GITR, and TGF-β, increased IFN-γ and IL-17 expression, and 
resulted in increased H3K4Me2 and H3K9Ac levels. In conven-
tional T cells, the compound increased IL-2 and IFN-γ production. 
Hence, the overall brunt of the effects was to dampen Treg genes 
of multiple genes within Foxp3+ Tregs than with effects on Treg 
trafficking or survival at tumor sites.
Encouraged by the in vivo data following Rcor1 targeting in 
Tregs, we turned to testing of recently characterized bifunctional 
CoREST inhibitors (33) in WT mice. These compounds were 
known to inhibit the proliferation of various tumor lines in vitro as 
well as having inhibitory effects on the growth of SK-MEL-5 mel-
anoma cell xenografts in immunodeficient mice (33). However, 
their utility in syngeneic models has not been reported. Since in 
Figure 8. Effects of CoREST complex inhibitor on human Tregs. (A) Human healthy donor Tregs were incubated with corin (1 μM) for 2.5 hours, washed 
twice, and incubated with CFSE-labeled, anti-CD3ε microbead-stimulated healthy donor PBMCs for 5–6 days. Representative data show impaired Treg 
suppressive function for CD4+ responder cells (CD8+ responder cells are shown in Supplemental Figure 8). (B) After suppression assays, cells were stained 
with fixable live/dead marker Zombie Yellow and Foxp3, cells were gated into CD4+CFSE –Zombie+ (= dead Treg), CD4+CFSE –Zombie–Foxp3– (= live exTreg), 
and CD4+CFSE –Zombie–Foxp3+ (= live Treg), to evaluate Treg stability (loss of Foxp3) and survival (% of Zombie– cells). (C) Statistical analysis of data shown 
in A; Tregs from 5 healthy donors and Tregs and responder PBMCs from 3 healthy donors were tested in 5 independent experiments (total of 12 suppres-
sion assays). Treg abilities to suppress divisions of CD4+ and CD8+ responders were analyzed separately; 1 sample t test with theoretical mean = 1. (D) 
Statistical analysis of data from B; data from 6 assays were pooled, Wilcoxon’s signed ranked test. (E) Cells were stained for Zombie Yellow, Foxp3, and 
CTLA-4. Viable CD4+CFSE–Zombie–Foxp3+ Tregs were gated and evaluated for CTLA-4 expression (MOF, percentage of positive cells) and Foxp3 MOF. Data 
were pooled from 6 assays. Wilcoxon’s signed ranked test. (F–J) Healthy donor PBMCs (from 5 different donors in 3 experiments) were incubated with corin 
(1 μM) and stimulated overnight with CD3ε/CD28 mAb-coated beads (1.3 beads/cell). (F) TIGIT and GITR expression tended to be decreased in viable CD4+-
Foxp3+ Tregs, but without significance, whereas CD127 expression significantly increased in the presence of corin. (G) Representative example of Foxp3 
expression in PBMCs and (H) Foxp3 MOF in viable CD4+Foxp3+ Tregs. (I and J) Statistics showing (I) decreased Treg numbers and (J) decreased MOF of Foxp3 
in human Tregs treated with corin. All tests in F through I are 1-sample t tests with Bonferroni’s correction for multiple comparisons, whereas data shown 
in J were evaluated by unpaired t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Data are shown as mean ± SD.
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Figure 9. CoREST complex inhibitor enhances antitumor immunity. (A) TC1 tumor volumes and AUC data were smaller in C57BL/6 mice treated with corin 
(10 mg/kg/d) vs. DMSO (n = 8–10/group). Analysis of the percentages of (B) CD4+ and CD8+ cells, (C) CD8+IFN-γ+ cells, (D) CD4+Foxp3+ cells, and (E) T cell 
activation markers (CD8+CD69+, CD4+CD69+, CD4+CD44hiCD62Llo, CD8+CD44hiCD62Llo) in lymph nodes, spleens, and tumors from corin- and DMSO-treated 
groups. Data are shown as mean ± SD, 8–10 samples/group. Student’s t test for unpaired data. *P < 0.05; **P < 0.01 vs. control.
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Foxp3YFP-cre mice (38). All mice were backcrossed on the C57BL/6 back-
ground at least 8 times and used at 6 to 8 weeks of age unless specified.
Plasmids and CoREST complex inhibitors. We purchased plasmids 
from Addgene and transiently expressed Flag-myc-tagged-Rcor1, 
Flag-myc-tagged-Rcor2, Flag-tagged-Foxp3, and HA-tagged-p300 in 
293T cells (23). Preparation of CoREST complex inhibitors JK-2-68 
and JKD-1-51 (corin) was described previously (33).
Co-IP and Western blotting. HEK-293T cells transfected with plas-
mids, as well as WT and Rcor1–/– Tregs, were lysed with RIPA buffer 
(MilliporeSigma, catalog SLBL7395V). Pulldown Abs were incubated 
with precleared samples for 2 hours at 4°C, then overnight with pro-
tein G–agarose (Invitrogen, catalog 15920-010). Cell lysates were 
separated by SDS-PAGE, transferred to PVDF membranes, and immu-
noblotted with the indicated Abs. We purchased Abs against Rcor1 
(Millipore, catalog MABN486), Foxp3 (Invitrogen, catalog 700914; 
eBioscience, catalog 14-4774-82), and histone H3 (Abcam, catalog 
ab1791) as well as Flag (catalog 14793), Myc (catalog 2272), HA (cata-
log 2367), Rcor2 (catalog ab37113), Lsd1 (catalog 2139), β-actin (catalog 
3700), Hdac1 (catalog 34589), Hdac2 (catalog 57156), Pcaf (catalog 
3378), T-bet (catalog 13232), β-catenin (catalog 8480), H3K9ac (catalog 
9649), H3K4me2 (catalog 9725), and ac–histone 3 (catalog9754S) from 
Cell Signaling Technology. Secondary HRP-conjugated Abs to mouse 
(catalog 7076), rat (catalog 7077) and rabbit (catalog 7074) IgG were 
purchased from Cell Signaling Technology. Unconjugated CD3 (clone 
145-2C11, catalog 553057) and CD28 (clone 37.51, catalog 553294) 
mAbs used for cell activation were purchased from BD. Full, uncut gels 
are included in the published online supplemental material.
Flow cytometry. Single-cell suspensions from lymph nodes, spleens, 
or tumors were prepared as previously described (33) and were stained 
with fluorochrome-conjugated mAbs from BD Biosciences, unless 
otherwise specified, that were directed against CD4 (Pacific Blue, Invi-
trogen, catalog MHCD0428), CD8 (Super Bright 645, eBioscience, 
clone 53-6.7, catalog 64-0081-82), Foxp3 (eFluor 450, eBioscience, 
clone FJK-16s, catalog 48-5773-82), CD62L (PE-Cy7, clone MEL-14, 
catalog 25-0621-82), IFN-γ (APC, clone XMG1.2, catalog 554413), 
CD44 (PE-Cyaine5, eBioscience, clone IM7, catalog 15-0441-83), 
and CD25 (APC, eBioscience, clone PC61.5, catalog 17-0251-82) and 
acquired on a Cytoflex (Beckman Coulter) flow cytometer.
Murine Treg suppression assays. For in vitro studies, 5 × 104 cell- 
sorted CD4+CD25– T cells and CD4+CD25+ Tregs from Foxp3YFP–Cre 
and Rcor1–/– mice isolated using the CD4+CD25+ Treg Isolation Kit 
(Miltenyi Biotec, catalog 130-091-041) were added to 96-well plates. 
Equal numbers of CFSE-labeled CD4+CD25– T cells and γ-irradiated 
APCs, isolated using a CD90.2 kit (Miltenyi Biotec, catalog 130-049-
101) plus CD3ε mAb (1 μg/mL) were cultured for 72 hours. After 72 
hours, proliferation of Teff cells was determined by flow and analysis 
of cell trace violet dilution. For in vivo Treg suppression assays, 1 × 
106 CD4+CD25– Thy1.1+ and 0.5 × 106 Tregs were injected i.v. into 
Rag1–/– mice. At 1 week, lymph node and spleen cells were stained with 
Thy1.1–PE and CD4–Pacific Blue, and the numbers of Thy1.1+ T cell 
determined (Cytoflex).
Corin and human Tregs. Human Treg suppression assays, using 
Tregs and Teff cells isolated from the peripheral blood of healthy donors, 
were performed as described (44). Human Tregs were preincubated for 
2.5 hours with corin (1 μM), washed 2 times, and used in suppression 
assays with CFSE-labeled healthy donor responder PBMCs, stimulated 
with anti-CD3ε microbeads, for 5 to 6 days. The ability of Tregs to sup-
and promote Th1 responses. The histone mark targeted by Lsd1, 
H3K4Me1/2, is typically associated more with enhancers than 
promoters. Hence, the observed effects of CoREST inhibition on 
gene expression could well be mediated by changes at enhancer 
sites rather than by direct effects at the various gene promoters.
Consistent with its immune-activating effects, JK-2-68 therapy 
in 2 distinct allograft models in which Treg function is required for 
long-term transplant survival resulted in allograft rejection. Finally, 
the more powerful and pharmacokinetically robust compound 
corin also impaired Treg suppressive function, markedly reduced 
growth of TC1 tumors in syngeneic mice, and was associated with 
increased host effector responses, including infiltration by activated 
CD8+ T cells producing IFN-γ. Although understanding the mech-
anisms underlying these events is likely more nuanced than what 
can be found in studies using conditional deletion of Rcor1 in Tregs, 
the transplant data indicate that the brunt of the effects of JK-2-68 
or corin therapy was on the Tregs more than conventional T cells, 
given that the compound induced acute rejection in Treg-depen-
dent models. Likewise, the cellular and molecular events in Treg- 
dependent tumor models in Rcor1–/– mice and inhibitor-treated 
mice have many similarities. In conclusion, while further studies of 
the roles of Rcor2 and Rcor3 in Tregs and immune responses gen-
erally are warranted, the current work shows that Rcor1 and the 
CoREST complex have important roles in Foxp3+ Tregs, such that 
therapeutic manipulation using CoREST complex inhibitors may be 
of benefit in cancer immunotherapy.
Methods
Mice. We used WT BALB/c and WT C57BL/6, Rag1–/– C57BL/6, 
CD90.1/B6, Rcor1fl/fl (catalog 025877), and Rcor2fl/fl (catalog 030004) 
mice from The Jackson Laboratory, plus previously described 
Figure 10. Schematic of the actions of the CoREST complex in Foxp3+ 
Tregs. In WT cells, Foxp3 recruits the CoREST complex, consisting of 
Rcor1, Hdac1 or Hdac2, and Lsd1, to repress expression of multiple genes, 
including IL-2 and IFN-γ. In the absence of Rcor1, recruitment of the 
CoREST complex by Foxp3 is markedly impaired, leading to derepression of 
multiple genes, including those encoding IL-2 and IFN-γ, and downstream 
signaling molecules, such as T-bet and STAT1.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 8 4 1jci.org   Volume 130   Number 4   April 2020
broadinstitute.org/morpheus/). Expression of individual genes was 
verified by qPCR. RNA was reverse-transcribed to cDNA (Applied 
Biosystems) and qPCR performed using TaqMan primer and probe 
sets; data were normalized to endogenous 18S rRNA, and relative 
expression was determined by the formula 2–ΔCT.
Immunofluorescence. Cell cytospins were fixed, permeabilized 
with 0.2% Triton X-100, blocked with normal goat serum for 1 hour, 
and incubated with Abs against Foxp3 (rat anti-mouse, eBioscience, 
catalog 14-5773-82) and Rcor1 (mouse anti-mouse, Millipore, cata-
log MABN486) diluted in 0.2% Triton X-100 overnight. After wash-
ing, cytospins were incubated with Alexa Fluor 488–conjugated 
goat anti–rat IgG (Invitrogen A11006) and Alexa Fluor 594–conju-
gated goat anti–mouse IgG (Invitrogen A11032), nuclei were stained 
with Hoechst (1 μg/mL, CST 4082), and cells were analyzed by flu-
orescent microscopy.
Cell lines and tumor model. TC1 cells, derived from mouse lung epi-
thelial cells that were immortalized with HPV-16 E6 and E7 and trans-
formed with the c-Ha-ras oncogene (46), were provided by Yvonne 
Paterson (University of Pennsylvania). The murine AE17.ova mesothe-
lioma cell line (provided by Delia Nelson, University of Western Aus-
tralia, Perth, Australia) was derived from mesothelioma cells develop-
ing in mice treated i.p. with asbestos and then stably transduced with 
chicken ovalbumin (47). Cells were grown in RPMI, 10% FBS, 2 mM 
glutamine, and 5 μg/mL of penicillin and streptomycin. Each mouse 
was shaved on its right flank and injected s.c. with 1.2 × 106 TC1 or 2 × 
106 AE17 tumor cells. Tumor volume was determined by the following 
formula: (3.14 × long axis × short axis × short axis)/6.
Statistics. Data were analyzed using GraphPad Prism 8.0. Data are 
presented as mean ± SD unless specified otherwise. Measurements 
between 2 groups were done with 2-tailed Student’s t test when data 
were normally distributed or Mann-Whitney U unpaired test when 
populations were not normally distributed. Groups of 3 or more were 
analyzed by 1-way ANOVA with corresponding Tukey’s multiple- 
comparisons test when normally distributed, or when not, using Kru-
skal-Wallis with Dunn’s multiple-comparisons test. Graft survival was 
evaluated with Kaplan-Meier followed by log-rank test; P < 0.05 was 
considered significant. For human Treg suppression assays, AUCs 
were calculated as described (44), followed by calculation of the ratios 
of AUCs to control Treg AUCs. For data presented as ratios, 1 sample 
t test (theoretical mean = 1) was applied for normally distributed data; 
otherwise, we applied Wilcoxon’s signed rank test (theoretical median 
= 1). When needed, all P values were corrected with Bonferroni’s test 
for multiple comparisons. Foxp3 median of fluorescence data were 
calculated using unpaired Student’s t test.
Study approval. Animal studies were approved by the Institutional 
Animal Care and Use Committee of the Children’s Hospital of Phila-
delphia (protocols 17-001047 and 19-000561).
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press divisions of CD4+ and CD8+ T cell responders was analyzed sepa-
rately. Five independent experiments were performed using 5 different 
healthy donors of normal Tregs and 3 different healthy donor respond-
ers, and most assays used pretreatment of Tregs with 1 μM of corin, such 
that data from 12 suppression assays were collected.
In addition, we assessed the effects of corin on human PBMCs. 
PBMCs from 5 healthy donors were incubated overnight with corin (1 
μM) and CD3ε/CD28 mAb–coated beads (1.3 beads/cell) and analyzed 
the next day by flow cytometry. In total, 18 markers were evaluated in 
CD45+Ghost–CD4+Foxp3+ Tregs (IFN-γ, IL-2, IL-4, IL-17, CD45RA, 
CD45RO, CD62L, CD69, PTEN, CD39, FAS, CD120b, GITR, TIGIT, 
CD127, CTLA4, HLA-DR, CD25). For cytokine production, PBMCs 
were stimulated the next day for 4 hours with PMA/ionomycin in the 
presence of Brefeldin. Human healthy donor Tregs did not produce 
substantial amounts of cytokines, so we noted only the markers whose 
expression was altered by the presence of corin.
Cardiac transplantation. Heterotopic cardiac allografts were per-
formed using BALB/c donors and WT or Rag1–/– recipients (C57BL/6 
background), as described (30). In adoptive transfer studies of 
Treg-dependent allograft survival, after their isolation using mag-
netic beads, Tregs (0.5 × 106) from WT or Rcor1–/– mice and Teff cells 
(1 × 106) from WT mice were injected i.v. into Rag1–/– mice bearing 
BALB/c cardiac allografts. In studies of costimulation blockade- 
dependent allograft tolerance, WT or Rcor1–/– allograft recipients were 
treated at the time of engraftment with CD154 mAbs plus 5 × 106 donor 
splenocytes (31). Graft survival was monitored as a function of the abil-
ity of Tregs to suppress Teff cell–dependent alloreactivity and cardiac 
allograft rejection. In related pharmacologic studies, Rag1–/– allograft 
recipients receiving adoptive transfer or WT recipients treated 
with CD154 mAbs were treated with CoREST inhibitors (10 mg/kg/d, 
14 days) from engraftment.
ChIP assays. We purchased EZ-Magna ChIP A Chromatin Immu-
noprecipitation Kits (Millipore). Teff cells or Tregs were fixed with 1% 
formaldehyde and fragmented by sonication. Chromatin was immu-
noprecipitated with Abs against acetyl-histone-H3, Hdac1, Hdac2 and 
Lsd1, and the resultant DNA was purified and analyzed by real-time 
PCR (Step-One, Applied Biosystems). Il2 and Ifng primer sets were 
reported previously (45); primers for T-box1 were as follows: forward, 
CGAATTCGCGCTGTATTAGCC; and reverse, GGCCTTTGCTGT-
GGCTTTAT.
RNA-Seq and real-time qPCR. RNA was isolated using RNeasy 
kits (QIAGEN), and RNA integrity and quantity were analyzed by 
NanoDrop ND-1000 and Nanochip 2100 Bioanalyzer (Agilent Tech-
nologies). Library preparation and RNA-Seq, genome mapping, and 
analysis were performed by Novogene on the Illumina Platform 
PE150; data were deposited in the National Center for Biotech-
nology Information’s Gene Expression Omnibus database (GEO 
GSE137137). Data were tested for differential expression significant 
analysis using the DESeq2 R package with the significant criterion of 
a FDR-adjusted P value (Padj) of less than 0.05 and further analyzed 
by Gene Ontology, KEGG, and Reactome database enrichments. To 
show Z scores, we included the 3 replicates per condition and cal-
culated Z score values via the following formula: Z = (x – μ)/σ, with 
x representing the fragments per kilobase million value, μ repre-
senting the mean per row (gene), and σ representing the standard 
deviation per row (gene). We then generated heatmaps using the 
Morpheus app on the Broad Institute’s website (https://software.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 8 4 2 jci.org   Volume 130   Number 4   April 2020
Address correspondence to: Wayne W. Hancock, Children’s Hos-
pital of Philadelphia, 916B Abramson Research Center, 3615 Civic 
Center Boulevard, Philadelphia, Pennsylvania 19104, USA. Phone: 
215.590.8709; Email: whancock@pennmedicine.upenn.edu.
Acknowledgments
This work was supported by NIH grants R01 AI12324 and R01 
CA177852 (to WWH) as well as R37GM62437 (to PAC), and speci-
fied plasmids were purchased from Addgene.
 1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. 
Regulatory T cells and immune tolerance. Cell. 
2008;133(5):775–787.
 2. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory 
T cells: mechanisms of differentiation and func-
tion. Annu Rev Immunol. 2012;30:531–564.
 3. Bauer CA, Kim EY, Marangoni F, Carrizosa 
E, Claudio NM, Mempel TR. Dynamic Treg 
interactions with intratumoral APCs pro-
mote local CTL dysfunction. J Clin Invest. 
2014;124(6):2425–2440.
 4. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 
programs the development and function of 
CD4+CD25+ regulatory T cells. Nat Immunol. 
2003;4(4):330–336.
 5. Hori S, Nomura T, Sakaguchi S. Control of regula-
tory T cell development by the transcription fac-
tor Foxp3. Science. 2003;299(5609):1057–1061.
 6. Van Gool F, et al. A mutation in the transcrip-
tion factor Foxp3 srives T helper 2 effector 
function in regulatory T cells. Immunity. 
2019;50(2):362–377.e6.
 7. Miguel A, et al. Silencing of Foxp3 enhances the 
antitumor efficacy of GM-CSF genetically mod-
ified tumor cell vaccine against B16 melanoma. 
Onco Targets Ther. 2017;10:503–514.
 8. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda 
M. Immunologic self-tolerance maintained by 
activated T cells expressing IL-2 receptor alpha-
chains (CD25). Breakdown of a single mechanism 
of self-tolerance causes various autoimmune 
diseases. J Immunol. 1995;155(3):1151–1164.
 9. Wang L, et al. Foxp3+ T-regulatory cells require 
DNA methyltransferase 1 expression to prevent 
development of lethal autoimmunity. Blood. 
2013;121(18):3631–3639.
 10. Sharma A, et al. Anti-CTLA-4 immunothera-
py does not deplete Foxp3+ regulatory T cells 
(Tregs) in human cancers. Clin Cancer Res. 
2019;25(4):1233–1238.
 11. Liu J, Cao X. Cellular and molecular regulation of 
innate inflammatory responses. Cell Mol Immu-
nol. 2016;13(6):711–721.
 12. Andrés ME, et al. CoREST: a functional  
corepressor required for regulation of neural- 
specific gene expression. Proc Natl Acad Sci U S A. 
1999;96(17):9873–9878.
 13. Humphrey GW, et al. Stable histone deacetylase 
complexes distinguished by the presence of 
SANT domain proteins CoREST/kiaa0071 and 
Mta-L1. J Biol Chem. 2001;276(9):6817–6824.
 14. You A, Tong JK, Grozinger CM, Schreiber SL. 
CoREST is an integral component of the CoR-
EST- human histone deacetylase complex. Proc 
Natl Acad Sci U S A. 2001;98(4):1454–1458.
 15. Hakimi MA, Bochar DA, Chenoweth J, Lane WS, 
Mandel G, Shiekhattar R. A core-BRAF35 com-
plex containing histone deacetylase mediates 
repression of neuronal-specific genes. Proc Natl 
Acad Sci U S A. 2002;99(11):7420–7425.
 16. Yang M, et al. Structural basis for CoREST- 
dependent demethylation of nucleosomes by 
the human LSD1 histone demethylase. Mol Cell. 
2006;23(3):377–387.
 17. Lee MG, Wynder C, Cooch N, Shiekhattar R. 
An essential role for CoREST in nucleosomal 
histone 3 lysine 4 demethylation. Nature. 
2005;437(7057):432–435.
 18. Shi Y, et al. Histone demethylation mediated by 
the nuclear amine oxidase homolog LSD1. Cell. 
2004;119(7):941–953.
 19. Chan FC, et al. An RCOR1 loss-associated 
gene expression signature identifies a prog-
nostically significant DLBCL subgroup. Blood. 
2015;125(6):959–966.
 20. Monaghan CE, et al. REST corepressors RCOR1 
and RCOR2 and the repressor INSM1 regulate 
the proliferation-differentiation balance in 
the developing brain. Proc Natl Acad Sci U S A. 
2017;114(3):E406–E415.
 21. Yao H, Goldman DC, Fan G, Mandel G, Fleming 
WH. The Corepressor Rcor1 is essential for  
normal myeloerythroid lineage differentiation. 
Stem Cells. 2015;33(11):3304–3314.
 22. Rudra D, et al. Transcription factor Foxp3 and  
its protein partners form a complex regulatory 
network. Nat Immunol. 2012;13(10):1010–1019.
 23. Liu Y, et al. Inhibition of p300 impairs Foxp3+ T 
regulatory cell function and promotes antitumor 
immunity. Nat Med. 2013;19(9):1173–1177.
 24. Hu X, Ivashkiv LB. Cross-regulation of signaling 
pathways by interferon-gamma: implications for 
immune responses and autoimmune diseases. 
Immunity. 2009;31(4):539–550.
 25. Sumida T, et al. Activated β-catenin in Foxp3+ 
regulatory T cells links inflammatory envi-
ronments to autoimmunity. Nat Immunol. 
2018;19(12):1391–1402.
 26. Laugesen A, Helin K. Chromatin repressive com-
plexes in stem cells, development, and cancer. 
Cell Stem Cell. 2014;14(6):735–751.
 27. Mohammad HP, et al. A DNA hypomethylation 
signature predicts antitumor activity of LSD1 
inhibitors in SCLC. Cancer Cell. 2015;28(1):57–69.
 28. Gu H, Liang Y, Mandel G, Roizman B. Compo-
nents of the REST/CoREST/histone deacetylase 
repressor complex are disrupted, modified, and 
translocated in HSV-1-infected cells. Proc Natl 
Acad Sci U S A. 2005;102(21):7571–7576.
 29. Gu H, Roizman B. Herpes simplex virus-infected 
cell protein 0 blocks the silencing of viral DNA by 
dissociating histone deacetylases from the CoR-
EST-REST complex. Proc Natl Acad Sci  
U S A. 2007;104(43):17134–17139.
 30. Wang L, et al. Foxp3+ regulatory T cell devel-
opment and function require histone/protein 
deacetylase 3. J Clin Invest. 2015;125(3):1111–1123.
 31. Hancock WW, Sayegh MH, Zheng XG, Peach 
R, Linsley PS, Turka LA. Costimulatory func-
tion and expression of CD40 ligand, CD80, 
and CD86 in vascularized murine cardiac 
allograft rejection. Proc Natl Acad Sci U S A. 
1996;93(24):13967–13972.
 32. Wang L, et al. Ubiquitin-specific protease-7 inhi-
bition impairs Tip60-dependent Foxp3+ T-reg-
ulatory cell function and promotes antitumor 
immunity. EBioMedicine. 2016;13:99–112.
 33. Kalin JH, et al. Targeting the CoREST complex 
with dual histone deacetylase and demethylase 
inhibitors. Nat Commun. 2018;9(1):53.
 34. Tao R, et al. Deacetylase inhibition promotes the 
generation and function of regulatory T cells. Nat 
Med. 2007;13(11):1299–1307.
 35. Barrios ÁP, et al. Differential properties of tran-
scriptional complexes formed by the CoREST 
family. Mol Cell Biol. 2014;34(14):2760–2770.
 36. Bankoti R, et al. Differential regulation of effec-
tor and regulatory T cell function by Blimp1. Sci 
Rep. 2017;7(1):12078.
 37. Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ. 
CD28 controls differentiation of regulatory 
T cells from naive CD4 T cells. J Immunol. 
2008;181(4):2285–2291.
 38. Rubtsov YP, et al. Regulatory T cell-derived inter-
leukin-10 limits inflammation at environmental 
interfaces. Immunity. 2008;28(4):546–558.
 39. Sojka DK, Hughson A, Fowell DJ. CTLA-4 is 
required by CD4+CD25+ Treg to control CD4+ 
T-cell lymphopenia-induced proliferation. Eur J 
Immunol. 2009;39(6):1544–1551.
 40. Paterson AM, et al. Deletion of CTLA-4 on 
regulatory T cells during adulthood leads 
to resistance to autoimmunity. J Exp Med. 
2015;212(10):1603–1621.
 41. Gokhale AS, Gangaplara A, Lopez-Occasio M, 
Thornton AM, Shevach EM. Selective deletion 
of Eos (Ikzf4) in T-regulatory cells leads to 
loss of suppressive function and development 
of systemic autoimmunity. J Autoimmun. 
2019;105:102300.
 42. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. 
Homeostatic maintenance of natural Foxp3(+) 
CD25(+) CD4(+) regulatory T cells by interleukin 
(IL)-2 and induction of autoimmune disease by IL-2 
neutralization. J Exp Med. 2005;201(5):723–735.
 43. Ono M, et al. Foxp3 controls regulatory T-cell 
function by interacting with AML1/Runx1. 
Nature. 2007;446(7136):685–689.
 44. Akimova T, Levine MH, Beier UH, Hancock 
WW. Standardization, evaluation, and area-
under-curve analysis of human and murine 
Treg suppressive function. Methods Mol Biol. 
2016;1371:43–78.
 45. Northrop JK, Thomas RM, Wells AD, Shen H. Epi-
genetic remodeling of the IL-2 and IFN-gamma 
loci in memory CD8 T cells is influenced by CD4 
T cells. J Immunol. 2006;177(2):1062–1069.
 46. Lin KY, et al. Treatment of established tumors 
with a novel vaccine that enhances major his-
tocompatibility class II presentation of tumor 
antigen. Cancer Res. 1996;56(1):21–26.
 47. Jackaman C, et al. IL-2 intratumoral immuno-
therapy enhances CD8+ T cells that mediate 
destruction of tumor cells and tumor-associated 
vasculature: a novel mechanism for IL-2. J Immu-
nol. 2003;171(10):5051–5063.
